<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30367358</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>27</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1880-4233</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>26</Day>                    </PubDate>                </JournalIssue>                <Title>Breast cancer (Tokyo, Japan)</Title>                <ISOAbbreviation>Breast Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12282-018-0929-6</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Ovarian function suppression (OFS) plus other endocrine treatment was recommended to hormone receptor (HR)-positive breast cancer by some guidelines recently. We performed this study to validate the survival benefits of OFS plus aromatase inhibitors (AI) or selective estrogen receptor modulators (SERM) in the real world.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">All premenopausal, HR-positive breast cancer patients diagnosed between 1996 and 2017 were identified. Eligible patients were classified into three groups according to their adjuvant endocrine treatment, including OFS plus AI, OFS plus SERM and SERM alone. The primary outcome is invasive disease-free survival (iDFS), whereas the secondary outcome is overall survival (OS). Cox proportional hazards models and propensity score adjusted models were used to compare the survival benefits in three groups.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 2838 patients, of which 246 received OFS plus AI, 175 received OFS plus SERM, and 2417 received SERM alone. Compared with SERM alone, OFS plus AI was associated with an improved iDFS (HR 0.59, 95% CI 0.36-0.96) and OS (HR 0.26, 95% CI 0.08-0.85). OFS plus SERM, however, was not significantly associated with extended iDFS or OS. Among patients older than 40Â years old, OFS plus AI was more effective than OFS plus SERM (HR 0.38, 95% CI 0.17-0.88) or SERM alone (HR 0.44, 95% CI 0.23-0.84) in terms of iDFS.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that OFS plus AI treatment may extend both iDFS and OS among premenopausal patients with hormone receptor-positive breast cancer in the real world.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hu</LastName>                    <ForeName>Kejia</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>He</LastName>                    <ForeName>Ping</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Peng</LastName>                    <ForeName>Qian</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhong</LastName>                    <ForeName>Xiaorong</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Deng</LastName>                    <ForeName>Ling</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xie</LastName>                    <ForeName>Yuxin</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Jiayuan</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Epidemiology, West China School of Public Health, Sichuan University, No. 16 Ren Min Nan Lu, Chengdu, Sichuan, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Hongping</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Epidemiology, West China School of Public Health, Sichuan University, No. 16 Ren Min Nan Lu, Chengdu, Sichuan, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lu</LastName>                    <ForeName>Donghao</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, People's Republic of China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zheng</LastName>                    <ForeName>Hong</ForeName>                    <Initials>H</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5802-330X</Identifier>                    <AffiliationInfo>                        <Affiliation>Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, People's Republic of China. hzheng@scu.edu.cn.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, People's Republic of China. hzheng@scu.edu.cn.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>81202099</GrantID>                    <Agency>National Natural Science Foundation of China</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>26</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Japan</Country>            <MedlineTA>Breast Cancer</MedlineTA>            <NlmUniqueID>100888201</NlmUniqueID>            <ISSNLinking>1340-6868</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Cohort study</Keyword>            <Keyword MajorTopicYN="N">Endocrine therapy</Keyword>            <Keyword MajorTopicYN="N">Ovarian function suppression</Keyword>            <Keyword MajorTopicYN="N">Survival</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30367358</ArticleId>            <ArticleId IdType="doi">10.1007/s12282-018-0929-6</ArticleId>            <ArticleId IdType="pii">10.1007/s12282-018-0929-6</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>